Transaction · 0002001011-24-000010

Reardon Andrew

Reardon Andrew, CLO, reported a transaction classified as other at LIGAND PHARMACEUTICALS INC involving 179.000000 shares for an estimated $10866.55. Reported holdings after the transaction were 15590.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

otherSEC transaction code JCLO
LGNDLIGAND PHARMACEUTICALS INC
Filing timeJan 04
Trade dateDec 29, 2023
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

LGND price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
LGND since 2024-01-04Filed 979 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
other
Code J
Identifier
0002001011-24-000010
Common Stock
Transaction date
Dec 29, 2023
Filed Jan 04, 2024, 04:07 PM · 6d delay
Shares
179 sh
$6.07k per share
Estimated value
$1.08M
Computed from shares × price
Holdings after
15.5k sh
Direct

Filing warnings

Notes recorded with this filing
2 warnings
delayed filingThe filing was reported 6 calendar days after the transaction date.
ambiguous transaction codeThe transaction code is missing or represents other activity; review the filing and footnotes.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Delayed Filing Direct Ownership
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF LEGAL OFFICER &

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).

Original filing · 0002001011-24-000010
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

LGND